The expansion spans a 14,500-sq-ft facility equipped with preformulation and formulation laboratories, a development suite, multiple good manufacturing practice (GMP) manufacturing suites, clinical packaging space, and warehouse. The new facility will allow the company to offer all drug development services in a single location.

Image courtesy of Eurofins.

With the expansion, Eurofins CDMO can support development and clinical manufacturing of oral solid dosage forms, including highly potent active pharmaceutical ingredients (APIs). The integration of the new drug product operations complements Eurofins' existing API development and manufacturing services by providing "quick-to-clinic" drug product strategy to help clients meet phase I/II products.

The new expansion will enhance Eurofins' drug product performance of APIs, from investigational new drug-enabling through to late-stage programs.

Eurofins DiscoverX expands program with Catalent
Eurofins DiscoverX has expanded its contract research organization certification program for bioassays with Catalent Biologics as the North American provider.

Eurofins Discovery supports COVID-19 research
Eurofins Discovery has announced that it aims to accelerate COVID-19 antiviral drug discovery research.